Value Line is regarded as the best independent research available. More than just recommendations, Value Line provides the rationale behind its picks for greater understanding.
- Don D., California
Industry Analysis: Biotechnology
The Biotechnology Industry is a highly volatile and unpredictable sector due to the scientifically intensive nature of the operations of companies that reside here. Markets served include medical, agricultural, environmental, and industrial. This industry emerged in the 1970s, with the main goal of enhancing the quality of human life. Biotech firms differ from conventional drug makers in that they utilize natural ingredients, as opposed to synthetic ones. Drugs are manufactured in a living system, i.e., a microorganism, plant or cell.
On the medical front, the endeavor to improve people's health is fulfilled through the creation of recombinant DNA (deoxyribonucleic acid), which is done by combining DNA sequences that do not naturally intermingle. With these DNA alterations, biotech companies have discovered treatments and therapies for a range of diseases, such as various forms of cancer, AIDS (acquired immune deficiency syndrome), Alzheimer's, and diabetes.
This industry seeks to optimize profitability via commercial success; an outcome that is the pinnacle of triumph for any biotech company. In order to reach such a position, companies must undertake laborious research. Biotechnology firms are among the most research-intensive organizations in the world. Their product pipelines, a vital component of expansion, are capital intensive.
Established companies typically fund their growth ventures with cash flow, but the debt and equity markets are sometimes tapped. Since many biotech companies are small, and cash is often scarce, external funding can be important. Patrons are typically big pharmaceutical companies or investment entities that stand to reap significant rewards from taking a stake in a drug that is commercialized. During difficult economic times, outside funding often dries up, as lenders become budget-constrained and more cautious about investments.
New discoveries for the treatment of diseases provide opportunities for growth and gains in stockholder value. Investors must, however, be willing to endure volatile or weak results in the short term. In many instances, a biotech firm may have to endure a lengthy period of sometimes-heavy losses before a drug comes on the market and yields operating benefits. The sales and earnings potential of a newly introduced commercial drug or treatment can be immense and remain positive for years. Indeed, patented biotech drugs enjoy a 12-year period of protection from competitors, guaranteeing investors favorable long-term returns.
Biotech drugs are expensive, however, and there is pressure from insurers, governments, and consumers to rein in healthcare costs. Some legislators regularly attempt to increase industry competition. If the period of market exclusivity is ever reduced, research-funding sources likely would be derailed and there would be a material negative impact on long-term sales and profitability. So far, the companies have held on to the prohibition period by successfully arguing that biotech drugs are scientifically complex, not easy to duplicate, and costly to develop. In fact, most prospective drugs never complete clinical trials and reach commercialization, since conclusive scientific evidence of efficacy, in many instances, proves elusive.
The U.S. Food and Drug Administration (FDA) is the primary regulator of the Biotech Industry. Before a drug makes it to market, it must traverse a strict clearance process set forth by the FDA. Statistically, the odds are great against a drug progressing through all the required clinical trial stages. For every 5,000 compounds discovered in pre-clinical studies, only about five make it to FDA approved status. There are four stages in the FDA trial process; in the last, drugs are placed on the market. Even after approved for use, drugs are subject to ongoing studies, in which patients are monitored for negative side effects. Recalls due to injuries and/or fatalities are not uncommon. Patents are nullified in the event of a recall. Companies invest much time and money to ensure a product's success. Recalls not only hurt sales and net income, but they may severely tarnish the reputation of a firm.
In addition to the FDA, other agencies have authority over the industry. Notably, the Environmental Protection Agency and Department of Agriculture hold sway, regarding the marketing of biotech offerings that might have a big effect on the areas under their respective control.
Uses of Cash
Like the majority of companies under our review, biotech firms must determine the best use of cash sourced from operations, and equity and debt issues. First and foremost, the goal is to achieve out-sized growth, and managements work to ensure fully funded research and development budgets. Much money is also spent on gaining approval of new drugs and bringing them to full production. Marketing and distribution require substantial funds, as well. Acquisitions are more common among large industry factors, which, at times, seek to bolster their lineup. In descending order, debt retirements, stock repurchases, and dividends are the least desirable uses of cash.
The nature of the operations of firms in the Biotech Industry makes these equities more suited to aggressive, risk-tolerant investors. Stock prices here can fluctuate dramatically, particularly in response to news developments concerning the success or failure of a particular drug. Investors must carefully consider a stock's risk/reward relationship. Often, they must be patient, willing to endure years of losses, before the benefits of a drug pipeline, in the form of long-term share-price appreciation, are realized.